Ditzingen, Germany - TRUMPF has again registered an increase in sales and orders over the previous year. Both values increased in the past fiscal year, ending June 30, 2015, by approximately 5%. According to preliminary calculations, total sales amounted to $2.9 billion (€2.723 billion) compared to $2.8 billion (€2.584 billion) the previous year, while order intake was $3.1 billion (€2.825 billion) compared to $2.9 billion (€2.7 billion).
Related: TRUMPF FY13/14 profits soar, thanks to record in increased revenue
"We're especially pleased that we've been able to compensate in both indicators for the discontinuation of our Medical Technology division in the first year after the sale, and in a generally difficult market environment as well," summarized Dr. Nicola Leibinger-Kammüller, president of the TRUMPF Group. On August 1, 2014, the TRUMPF Group had sold its medical technology division to US medical technology manufacturer Hill-Rom Holdings. In the 2013/14 fiscal year, medical technology still contributed 185 million euros' [$203 million] worth of sales of the TRUMPF Group.
"We generated the past fiscal year's growth in our core business," says Leibinger-Kammüller, "and were able to reinforce it with targeted acquisitions." These included the acquisition of EHT in Teningen and JK Lasers in Great Britain, as well as the strengthening of regional markets in Eastern Europe and Turkey.
"With a book-to-bill ratio of above one—that is, the fact that the order intake is higher than sales—we have created good foundations for new fiscal year of 15/16 that has just begun," says Leibinger-Kammüller.
TRUMPF will be presenting the final result, including the company's profits, at the press conference on October 22, 2015.